Ann: Imagion Biosystems December 2021 Investor Newsletter, page-20

It's the nature of trials like ours that Co's will not update the market on progress unless a cohort
of patients is achieved (and tested). Over the years I have found this process to be perfectly
normal when compared to other ASX listed Co's undertaking a similar trial process - Whatever,
the rationale is on this process that appears indirect or evasive by some fellow investors,
It's common and it is there to be evaluated and judged by each of us I guess.

So, rightly or wrongly, that is the strategy the Co have employed...and they have commented
(obliquely some may say) on that specific topic in today's "Investor Newsletter". With no adverse
news to date on testing of patient/s (mandatory under the ASX continuous disclosure rules),
the signs are there that the tech is progressing positively. Let's see...to me, it does look very
promising. In that same vein, I can understand that other investors may see things differently.